Navigation Links
Verenium Regains Compliance With Nasdaq Continued Listing Requirement
Date:1/13/2009

alysts of biochemical reactions. For more information on Verenium, visit http://www.verenium.com.

Forward Looking Statements

Statements in this press release that are not strictly historical are "forward-looking" and involve a high degree of risk and uncertainty. These include statements related to the Company's operations, capabilities, commercialization activities, target markets and cellulosic ethanol facilities, all of which are prospective. Such statements are only predictions, and actual events or results may differ materially from those projected in such forward-looking statements. Factors that could cause or contribute to the differences include, but are not limited to, risks associated with Verenium's new and uncertain technologies, risks associated with the costs, labor requirements and labor availability associated with Verenium's demonstration plant, risks associated with Verenium's ability to obtain additional capital to support its planned operations, risks associated with Verenium's dependence on patents and proprietary rights, risks associated with Verenium's protection and enforcement of its patents and proprietary rights, technological, regulatory, competitive and other risks related to development, production, and commercialization of cellulosic ethanol and other biofuels and the commercial prospects of those industries, Verenium's dependence on existing collaboration, manufacturing, and/or license agreements, and its ability to achieve milestones under existing and future collaboration agreements, the ability of Verenium and its partners to commercialize products (including by obtaining any required regulatory approvals) using Verenium's technologies and timing for launching any commercialized products, the ability of Verenium and its collaborators to market and sell any products that it or they commercialize, the development or availabilit
'/>"/>

SOURCE Verenium Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Verenium Corporation to Speak at the Credit Suisse Alternative Energy Conference
2. Verenium Corporation to Announce Third Quarter 2008 Financial Results
3. Verenium Corporation to Present at the William Blair & Company 2008 Small-Cap Growth Stock Conference
4. Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference
5. Verenium Appoints John F. Dee to Board of Directors
6. Verenium Reports Financial Results for the First Quarter 2008
7. Verenium Corporation to Present at Piper Jaffray Clean Technology & Renewables Conference
8. Verenium Explores Bacterial Genes Inside Termite Guts to Understand How Wood is Broken Down and Converted to Energy
9. Verenium Corporation to Present at the Pacific Growth Equities 2007 Clean Technology & Industrial Growth Conference
10. Verenium Advances Its Development Work With Cargill on a New Food-Related Product
11. Verenium Corporation to Present at the Upcoming Cowen and Company Clean Energy Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... ... July 29, 2015 , ... Costello served as Lead Levee Design Engineering ... the Orange County, Texas area from future storm surge flooding, such as occurred in ... potential levee alignment alternatives for providing protection, Costello also balanced socio-economic and environmental ...
(Date:7/29/2015)... MA (PRWEB) , ... July 29, 2015 , ... ... Sherley says the company is making good progress in evaluating the full range ... adult tissue stem cells. Adult tissue stem cells perform the day-to-day renewal and ...
(Date:7/28/2015)... LONDON , July 29, 2015 ... on acquiring, rapidly developing and commercialising ... human health   Highly experienced management team; ...     Mereo BioPharma Group Ltd ... successfully raised $119m ( c. £76.5m), gross, from blue ...
(Date:7/28/2015)... ... July 29, 2015 , ... The new Xsample 530 sample changer for vials can ... of liquid viscosities – from less than 12,000 mPas (internal air) up to 36,000 (external ... What immediately catches the eye about Xsample 530 is its removable magazine, which is easily ...
Breaking Biology Technology:Preventing Storm Surge Flooding in Houston 2Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 2Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 3Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 4Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 2Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 3Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 4Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 5Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 6Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 7Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 8Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 9Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 10Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 11New Moves in Automatic Sample Handling: Introducing Xsample 530 2
... Patrick Dempsey is speaking out to help connect cancer ... Breakaway from Cancer® initiative. "Cancer ... diagnosed with ovarian cancer," explained Dempsey.  "I remember the feelings ... come to terms with the fear and shock of the ...
... Christine Pierre, president of RxTrials, Inc ., today named ... has been head of prime sites for Quintiles, will begin on ... "I have collaborated with Adam for 16 years and have ... what really stands out for me is his integrity. Yes, he brings ...
... Inc. (Nasdaq: NVAX ) has been named ... of Maryland (TCM), the largest technology trade group serving ... was recognized as the firm that best exemplifies the ... presence and leadership in Maryland. The criteria ...
Cached Biology Technology:Patrick Dempsey Teams up With Breakaway from Cancer® to Help Connect Cancer Patients to Free Resources 2Patrick Dempsey Teams up With Breakaway from Cancer® to Help Connect Cancer Patients to Free Resources 3RxTrials Announces Hiring Adam Chasse as VP of Business Development 2RxTrials Announces Hiring Adam Chasse as VP of Business Development 3Novavax Named Biotechnology Firm of the Year by Tech Council of Maryland 2
(Date:6/25/2015)... According to a new ... Area), Technology, Material (Optical Prism, Piezoelectric, Capacitive & ... Others) & Geography - Global Forecast to 2014 ... is expected to reach $14,500.07 Million by 2020, ... Browse 76 market Tables and 109 Figures spread ...
(Date:6/25/2015)... -- TAKE Solutions Ltd., a global business technology solutions provider, ... and Trademark Office (USPTO) for its "Method for Optimizing ... Accelerators to reduce the time taken to standardize trial ... the accelerators), thus reducing time to market. ... heart of the patented Clinical Data Standardization Process are ...
(Date:6/24/2015)... , June 24, 2015 This report ... over the next six years. It contains an analysis ... industry, along with their impact from the short, medium, ... also discusses the industry, market, and technology trends that ... the need of concerned authorities to efficiently manage the ...
Breaking Biology News(10 mins):Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4TAKE Solutions Awarded Patent By USPTO 2Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2
... Barr of the University,s Faculty of Biological Sciences are working ... bank of molecular signatures that will help identify the severity ... the team is barcoding different strains of influenza virus and ... the onset of asthma in young children. "Diseases such ...
... of biological inheritance is DNA replication a tightly coordinated ... thousands of different sites across the genome. If that copying ... cells with missing or extra genetic material, a hallmark of ... University of North Carolina School of Medicine scientists have ...
... ant species and a carnivorous plant, the ants contribute to ... provide significant amounts of nutrients derived from their wastes. This ... May 9 in the open access journal PLoS ... bicalcarata grows in the nutrient-poor peatswamp forests of Borneo ...
Cached Biology News:Virus 'barcodes' offer rapid detection of mutated strains 2DNA replication protein also has a role in mitosis, cancer 2
Purified anti-SOCS3...
Tumor Suppressor Sampler Kit 10 mu g each...
AMAP Multi Site-directed Mutagenesis Kit Research Focus: other Storage Temperature: -20C Shipping Temperature: dry ice...
Umbilical cord blood eosinophils, For immunohistochemistry (IHC)...
Biology Products: